Vertex licenses TreeFrog’s tech to upscale cell therapy manufacturing for diabetes candidates
Vertex will pay $25 million upfront for TreeFrog Therapeutics’ cell manufacturing technology that can help boost production of its early-phase type 1 diabetes assets.
In exchange for an exclusive license for the cell production tech, dubbed C-Stem, TreeFrog would also receive an equity investment from Vertex and up to $215 million in milestone payments, depending on how successful the tech is in scaling up fully differentiated pancreatic islet cells that can produce insulin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
